These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Therapeutic effect of capsule xinganbao on schistosomal hepatocirrhosis].
    Author: Zhang HX, Cheng CX, Yi JH.
    Journal: Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2011 Jun; 23(3):284, 291. PubMed ID: 22164492.
    Abstract:
    A total of 118 patients with schistosomal hepatocirrhosis were divided into an experiment group (62 cases) and a control group (56 cases), and the former received capsule Xinganbao and the latter received conventional medicine for 6 months. The reductions of serum HA, LN and PCIII were more notable in the experiment group than in the control group (P < 0.05). The clinical symptoms, physical signs, and liver function improved in both groups, and there were no significant differences between two groups. In conclusions, capsule Xinganbao has a good effect on hepatic fibrosis.
    [Abstract] [Full Text] [Related] [New Search]